The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
about
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis CRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseChronic hepatitis C: This and the new era of treatmentIndian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection: Update 2016.Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.Combination of sofosbuvir, pegylated-interferon and ribavirin for treatment of hepatitis C virus genotype 1 infection: a systematic review and meta-analysisSystematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.Direct-acting antivirals for chronic hepatitis C.Treatment of hepatitis C virus infection for adults and children: Updated Swedish consensus recommendations.SASLT guidelines: Update in treatment of Hepatitis C virus infection.Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2)Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?Lower response to simeprevir and sofosbuvir in HCV genotype 1 in routine practice compared with clinical trials.Liver regeneration - mechanisms and models to clinical application.Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time.Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis.Managing drug-drug interactions with new direct-acting antiviral agents in chronic hepatitis C.Sofosbuvir plus simeprevir for the treatment of genotype 1 chronic hepatitis C: a review of evidence.Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience.Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.Randomized trial of combined triple therapy comprising two types of peginterferon with simeprevir in patients with hepatitis C virus genotype 1b.Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans.Photo-induced drug eruption in a patient on combination simeprevir/sofosbuvir for hepatitis C.Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST.Direct-acting antivirals for chronic hepatitis CExpert opinion on the management of hepatitis C infection in Kuwait
P2860
Q26741123-1B79F856-9078-4331-9319-0218140896F5Q26752433-ACBB69A6-6BE5-439D-A2E4-7D505C4B35FDQ26775011-DCD892EA-78CE-4773-925C-5EF8CFB0835BQ30355190-1359B45E-F108-4C75-9312-FA3BFFD46D5FQ30375305-A8A293EC-32BB-4FE3-95F6-CDAAA19FFA3BQ31160142-CCFE267B-F57D-4E45-BC1A-98A739DE5F55Q33582596-8524B61E-7F5B-4C13-A5A4-BF54B2248FABQ34522481-E45022C6-154B-420E-A3DD-8012FC5D631FQ34557595-5CA968AB-EBAB-433F-9645-037A5BFD2FC2Q36519126-F6243CBF-C976-4E85-8BED-36609C54F6B0Q37216507-83AFD5D4-B226-4CFA-9489-2D1843A2EDD6Q37631758-A16E6566-5979-4EC2-92FE-365C22594E60Q38665683-0491FCEC-6C3C-4830-B7DC-BCA7A20C2AFCQ38804680-5B40B95A-48AF-49A1-AE06-8C235309C707Q38879963-16DF9958-9D4F-46A9-BFD4-BD4BB0E3DBD8Q38893104-3E9EB487-6190-4F0D-8B8A-8C703EC064F1Q38903835-38369999-189A-426C-92F5-09587C44B258Q38929010-7ECD1EBD-1868-4059-9A50-D377C13BD0B2Q38954096-EF688E26-8E4F-4FB3-AEE2-11EE2397F7C2Q38992214-D9B08285-FBB4-48B1-B968-C2CCE03D5D69Q40035445-09E87B54-CDAE-4EAB-A98C-F09C3183CAB4Q40125281-54322D30-D9B5-4761-92CF-26D765DA82E3Q40292229-B175D469-33F6-430A-96DD-6614C8229A05Q40771120-2CB04932-30DB-47A4-8447-7F278890C67CQ40795101-4D9488F6-E0BB-4074-995F-7EC5EE726499Q41828118-513D1467-EB19-4A2B-879F-A555E10D2392Q45339726-ADEE3526-4ED0-4E37-AFA5-443F66FEFEDBQ50277989-8A63321B-8F3B-4623-93C0-F16EE3317229Q50881536-A17DC1F9-D7F4-456F-AF69-AAA5B1609AEEQ57389418-9963E426-5192-49CC-BFFD-7D5DCD5A9800Q57490314-DC48F931-F1C1-4CB3-A2E5-6E5C23EBD755
P2860
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The combination of simeprevir ...... ted Child's class A cirrhosis.
@en
type
label
The combination of simeprevir ...... ted Child's class A cirrhosis.
@en
prefLabel
The combination of simeprevir ...... ted Child's class A cirrhosis.
@en
P2093
P1433
P1476
The combination of simeprevir ...... ted Child's class A cirrhosis.
@en
P2093
Brian L Pearlman
Carole Ehleben
Michael Perrys
P304
762-70.e2; quiz e11-2
P356
10.1053/J.GASTRO.2014.12.027
P407
P577
2014-12-31T00:00:00Z